Elevated fasting insulin, visceral adiposity, non-alcoholic fatty liver disease, and chronic systemic inflammation are not merely cardiovascular or endocrine risk factors they represent a hostile cellular environment in which neoplastic transformation is more likely to occur, progress, and evade immune surveillance
Demand for Ozempic and its kin is tremendous, but many people cant access these drugs because of cost and supply issues
Key pharmaceutical players, including Novo Nordisk and Eli Lilly, are conducting innovative clinical trials, while strategic collaborations with biotech startups accelerate R&D
Therefore, we focus on the biological characteristics of GLP-1, render an overview of the mechanism of GLP-1 effects in diseases, and investigate the potential of GLP-1 analogues for the treatment of related diseases in this review